Latest Breaking News On - தனுஷ்ரீ ஜெயின் - Page 1 : comparemela.com

3 ASX healthcare shares with big news coming

3 ASX healthcare shares with big news coming
fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.

United statesBell potterElyse shapiroJohn hesterTanushree jainTela bio incAroa biosurgery ltdDrug administrationKazia therapeutics ltdMesoblast limitedTherapeutics ltdBiosurgery ltdஒன்றுபட்டது மாநிலங்களில்மணி பாடர்ஜான் ஹெஸ்டர்தனுஷ்ரீ ஜெயின்

Mesoblast (MESO) Q3 2021 Earnings Call Transcript

MESO earnings call for the period ending March 31, 2021.

United statesJason mccarthySilviu itescuLouise chenJohn hester bell potterKennen mackayJosh muntnerTanushree jain bell potterLouise chen cantor fitzgeraldJohn hesterFred grossmanTanushree jainOffice of tissueMaxim groupOncologic drugs advisory committeeJason mccarthy maxim group analyst

Troubled Mesoblast secures crucial cash buffer from surprise US backer

Troubled Mesoblast secures crucial cash buffer from surprise US backer We’re sorry, this service is currently unavailable. Please try again later. Dismiss Normal text size Advertisement Mesoblast has been given a financial lifeline that analysts expect will give it an 18-month cash buffer after the drug company secured a $138 million investment from a surprise US backer. The ASX-listed $1.45 billion stem cell treatments maker unveiled an unexpected new partner on Tuesday, confirming it had sealed a $US110 million ($138 million) deal with a US investor group led by surgery clinics business, SurgCenter Development. Mesoblast had been in a trading halt since Friday, when its half-year report showed it was running at a $US48.9 million half-year loss. Its auditor PwC said a private placement and future partnership payments were key to the company continuing as a going concern.

United statesNew south walesBell potterSilviu itescuTanushree jainTenet healthSydney morningஒன்றுபட்டது மாநிலங்களில்புதியது தெற்கு வேல்ஸ்மணி பாடர்தனுஷ்ரீ ஜெயின்கொள்கை ஆரோக்கியம்சிட்னி காலை

Investors in drugmaker Mesoblast sweat on crucial capital raising

Investors in drugmaker Mesoblast sweat on crucial capital raising Weâre sorry, this service is currently unavailable. Please try again later. Dismiss Save Normal text size Advertisement Drugmaker Mesoblast has been forced to go to the market to secure a private placement as it waits for critical milestone payments from partners to come through, having burnt through $77 million in cash in past six months. Shares in the stem cell treatments developer were halted on Friday ahead of details of on an âannouncement by the company in relation to a proposed private placement to a targeted industry investorâ. Later that evening Mesoblast dropped its half-year financial results that showed the business was running at a $US48.9 million loss, had $US77.5 million in cash on hand and needed cash from its existing partnerships to land âto meet our forecast expenditure and continue as a going concernâ. The firm had outflows of $US60.1 million for operating activities

Bell potterSilviu itescuTanushree jainDrug administrationமணி பாடர்தனுஷ்ரீ ஜெயின்